definiens: shall mean any modification to ANDA No . 202090 ( as supplemented or amended as of the Execution Date or, solely to incorporate any modifications described in this definition, thereafter ) that does not materially ch ange the active ingredient, concentration, dosage f orm, indication, reference listed drug ( unless the reference listed drug is first changed for the NDA Product ), or AB r ating of any generic product defined by such ANDA and/or does no t add one or more additional active ingredients to any generic product defined by such ANDA . For the avoid ance of doubt, a modification of such ANDA to add a second active ingredient to any generic product defined by such ANDA, to materially change C-2 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE S ECURITIES EXCHANGE ACT OF 1934, AS AMENDED